Table 1 Sample characteristics.

From: An executive function subtype of PTSD with unique neural markers and clinical trajectories

  

Total Sample (N = 368)

  

Imp

Avg

Abv

  
 

n = 55

n = 254

n = 59

  

Demographics

 

Mean (SD)

Mean (SD)

Mean (SD)

β

p value

 

Age

32.53 (7.48)

32.00 (8.68)

31.08 (7.37)

−0.05

0.351

 

Gender (% male)

80%

89.76%

93.22%

5.70a

0.058

 

Education

13.93 (1.69)

13.98 (1.97)

14.46 (2.02)

0.08

0.137

 

Verbal Ability

99.31 (11.87)

103.87 (10.87)

110.19 (9.23)

0.27

<0.001

 

Raceb

     
 

 American Indian

0.00%

0.00%

1.69%

  
 

 Asian

1.82%

3.15%

1.69%

  
 

 Black

16.36%

7.48%

5.08%

  
 

 Pacific Islander

3.64%

0.00%

0.00%

  
 

 White

58.18%

74.41%

94.92%

  
 

Medications

     
 

 Antidepressant

27.27%

26.80%

24.56%

0.14a

0.933

 

 Antiepileptic

5.45%

2.00%

3.51%

2.14a

0.343

 

 Sedative/Hypnotic

5.45%

8.80%

7.02%

0.775a

0.677

 

 Pain

34.55%

26.00%

36.84%

3.62a

0.164

Clinical

      
 

CAPS-IV Total

55.27 (29.60)

51.60 (28.58)

44.17 (28.15)

−0.11

0.038

 

Re-experiencing

14.05 (9.68)

13.38 (9.58)

12.03 (9.30)

−0.06

0.255

 

Avoidance/Numbing

21.25 (13.20)

19.31 (13.00)

16.59 (12.41)

−0.1

0.054

 

Hyperarousal

19.96 (9.94)

18.91 (9.34)

15.54 (9.11)

−0.13

0.011

 

PTSD Diagnosis

63.64%

66.14%

54.24%

2.94a

0.230

 

Mild TBI

45.45%

43.70%

45.76%

0.12a

0.942

 

Alcohol Use

7.58 (4.86)

6.01 (3.57)

5.76 (4.40)

−0.13

0.015

 

Anxiety

8.94 (8.43)

6.68 (7.44)

6.46 (8.03)

−0.09

0.098

 

Depression

9.70 (9.34)

9.08 (9.77)

8.42 (9.93)

−0.04

0.491

 

Sleep Dysfunction

11.04 (4.57)

9.85 (4.74)

8.85 (4.55)

−0.13

0.016

 

Chronic Pain

32.29 (22.91)

30.83 (25.12)

26.68 (24.81)

−0.07

0.236

Cognitive

      
 

 Attention

−0.35 (0.49)

0.05 (0.56)

0.43 (0.51)

0.37

<0.001

 

 Memory

−0.64 (0.85)

−0.29 (1.01)

−0.01 (0.85)

0.18

<0.001

  1. β and p values are from regression analyses in which EF groups predicted demographics, clinical, and cognitive measures. Significant effects are bolded, and these were included as covariates in follow-up functional connectivity and chronicity analyses. Re-experiencing, avoidance/numbing, and hyperarousal scales are symptom clusters from the CAPS-IV.
  2. EF executive functioning, Imp impaired EF, Avg average EF, Abv above-average EF, PTSD+ Individuals with a PTSD diagnosis, PTSD− Individuals without a PTSD diagnosis, Verbal Ability total score from the Wechsler Test of Adult Reading, CAPS-IV Total total score from the Clinical-Administered PTSD Scale for DSM-IV, Mild TBI Mild military TBI flag from the Boston Assessment of Traumatic brain injury-lifetime, Alcohol Use average number of drinks on a drinking day from the Lifetime Drinking History, Depression and Anxiety total scores from Depression Anxiety Stress Scale, Sleep Dysfunction global sleep score from the Pittsburgh Sleep Quality Index global sleep score, Chronic Pain average pain in the last month score from the McGill Short Form.
  3. aχ2 test was used to test for proportional differences across EF groups.
  4. bNo statistical test conducted due to the small size for participants that identified as American Indian, Asian, Black, and Pacific Islander.